- Home
- ALXO vs MNDO Comparison
ALXO vs MNDO Comparison
Compare ALXO & MNDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- MNDO
- Stock Information
- Founded
- ALXO 2015
- MNDO 1995
- Country
- ALXO United States
- MNDO Israel
- Employees
- ALXO N/A
- MNDO N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- MNDO EDP Services
- Sector
- ALXO Health Care
- MNDO Technology
- Exchange
- ALXO Nasdaq
- MNDO Nasdaq
- Market Cap
- ALXO 24.0M
- MNDO 23.0M
- IPO Year
- ALXO 2020
- MNDO 2000
- Fundamental
- Price
- ALXO $1.17
- MNDO $1.15
- Analyst Decision
- ALXO Strong Buy
- MNDO
- Analyst Count
- ALXO 6
- MNDO 0
- Target Price
- ALXO $3.30
- MNDO N/A
- AVG Volume (30 Days)
- ALXO 1.7M
- MNDO 59.5K
- Earning Date
- ALXO 08-12-2025
- MNDO 08-11-2025
- Dividend Yield
- ALXO N/A
- MNDO 19.47%
- EPS Growth
- ALXO N/A
- MNDO N/A
- EPS
- ALXO N/A
- MNDO 0.15
- Revenue
- ALXO N/A
- MNDO $20,155,000.00
- Revenue This Year
- ALXO N/A
- MNDO N/A
- Revenue Next Year
- ALXO N/A
- MNDO N/A
- P/E Ratio
- ALXO N/A
- MNDO $7.73
- Revenue Growth
- ALXO N/A
- MNDO N/A
- 52 Week Low
- ALXO $0.40
- MNDO $1.02
- 52 Week High
- ALXO $2.59
- MNDO $2.13
- Technical
- Relative Strength Index (RSI)
- ALXO 75.79
- MNDO 35.65
- Support Level
- ALXO $0.80
- MNDO $1.10
- Resistance Level
- ALXO $1.04
- MNDO $1.27
- Average True Range (ATR)
- ALXO 0.11
- MNDO 0.07
- MACD
- ALXO 0.05
- MNDO -0.01
- Stochastic Oscillator
- ALXO 96.85
- MNDO 36.11
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About MNDO MIND C.T.I. Ltd.
MIND C.T.I. Ltd develops, manufactures, markets, and implements real-time and off-line convergent billing and customer care software solutions. It derives revenue from the sale of software products and services in two reportable segments, namely Billing and Related Services, which derives key revenue, and Messaging. The company has three product lines: Product Line A- billing and customer care solutions for service providers; Product Line B - call accounting and call management solutions for enterprises; and Product Line C - mobile messaging, communication, and payment solutions. Geographically, the company operates in the Americas, Europe, Asia Pacific and Africa, and Israel. It earns maximum revenue from Europe.